Dermatology NewsAnybody for a nanobody? Novel psoriasis therapy impresses in phase 2bFebruary 10, 2021PsoriasisPsoriatic Arthritis
Dermatology NewsRheumatologic disease activity an important influencer of COVID-19 death riskFebruary 5, 2021COVID-19 UpdatesPsoriatic ArthritisInfectious Diseases
Dermatology NewsFDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)February 5, 2021Psoriatic ArthritisPediatrics
Dermatology NewsIn head-to-head trial, two biologics differ markedly for control of psoriasisFebruary 4, 2021PsoriasisPsoriatic Arthritis
Dermatology NewsGuselkumab maintains psoriasis efficacy long after discontinuationJanuary 26, 2021PsoriasisPsoriatic Arthritis
Dermatology NewsDeucravacitinib offers biologic-like psoriasis efficacy in oral formJanuary 8, 2021PsoriasisPsoriatic Arthritis
Dermatology NewsOsteoporosis prevalence in PsA similar to general populationJanuary 6, 2021Psoriatic Arthritis
Dermatology NewsCOVID-19 vaccines: Safe for immunocompromised patients?December 17, 2020COVID-19 UpdatesInfectious DiseasesPsoriasisPsoriatic Arthritis
Dermatology NewsSynovial, skin gene expression differences may explain PsA treatment responsesDecember 11, 2020Psoriatic ArthritisPsoriasis
International expert group agrees on redefining psoriasis severity December 1, 2020PsoriasisPsoriatic Arthritis
Dermatology NewsThe case for anti–IL-17 agents as first-line biologics in psoriatic arthritisNovember 30, 2020Psoriatic ArthritisPsoriasis
Dermatology NewsExpanded indications likely for apremilastNovember 30, 2020PsoriasisPediatricsPsoriatic Arthritis
Dermatology NewsTNF inhibitor–induced psoriasis treatment algorithm maintains TNF inhibitor if possibleNovember 25, 2020PsoriasisPsoriatic Arthritis
Dermatology NewsTildrakizumab for psoriasis shows durable efficacy over 5 yearsNovember 19, 2020PsoriasisPsoriatic Arthritis
Dermatology NewsChronic inflammatory diseases vary widely in CHD risk November 15, 2020PsoriasisPsoriatic Arthritis
